Related Experiment Videos
Regulation of GTP biosynthesis
G Weber1, H Nakamura, Y Natsumeda
1Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46202-5200.
Advances in Enzyme Regulation
|January 1, 1992
Summary
GTP biosynthesis enzymes are elevated in cancer, driving cancer growth. Targeting these enzymes with chemotherapy, like tiazofurin and hypoxanthine, shows promise for cancer treatment.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- GTP biosynthesis involves complex enzyme interactions, including IMPDH and GPRT.
- Enzyme activities are crucial for regulating GTP production in both normal and neoplastic cells.
Purpose of the Study:
- To investigate the role of GTP biosynthesis enzymes in neoplastic transformation and cancer.
- To explore the potential of enzyme-pattern-targeted chemotherapy for cancer treatment.
Main Methods:
- Kinetic assays and immunotitration were used to measure enzyme activities and amounts.
- Cell culture experiments, including HL-60 cell differentiation, were performed.
- Synergistic chemotherapy trials with tiazofurin and hypoxanthine were conducted in patients and cell lines.
Main Results:
- Activities of key GTP biosynthetic enzymes (IMPDH, GPRT, GMP synthase) are elevated in cancer cells.
- Cancer cells exhibit increased de novo and salvage guanylate production pathways.
- GMP reductase activity is inversely regulated with IMPDH during HL-60 cell differentiation.
- Tiazofurin and hypoxanthine demonstrated synergistic effects in cancer treatment.
Conclusions:
- Elevated GTP biosynthesis is a hallmark of neoplastic transformation and cancer progression.
- Targeting GTP biosynthesis enzymes offers a promising strategy for novel cancer therapies.
- Understanding enzyme regulation, particularly GMP reductase, is vital for optimizing cancer treatment approaches.